Method for preparing atopic dermatitis-like 3-dimensional skin tissue model and method for screening therapeutic agents for atopic dermatitis using the same
A 3D skin tissue model treated with IL-4, IL-13, IL-22, and TNF-α, and optionally Staphylococcus aureus, effectively mimics atopic dermatitis, enabling accurate screening of therapeutic agents.
Patent Information
- Application Number
- KR1020230016327
- Authority / Receiving Office
- KR · KR
- Patent Type
- Patents
- Current Assignee / Owner
- Filing Date
- 2023-02-07
- Publication Date
- 2026-11-06
- Estimated Expiration
- 2043-02-07
AI Technical Summary
Current methods for modeling atopic dermatitis lack an effective animal-alternative that accurately reflects the human biological environment, hindering the development and screening of therapeutic agents.
A method involving the treatment of a three-dimensional skin tissue model with a cytokine complex composed of IL-4, IL-13, IL-22, and TNF-α, and optionally Staphylococcus aureus, to mimic atopic dermatitis characteristics, including the expression of specific skin barrier, epidermal cell differentiation factors, and pro-inflammatory cytokines.
The method produces a 3D skin tissue model that accurately mimics atopic dermatitis, allowing for the evaluation of therapeutic agents by altering the expression of relevant factors and providing a reliable animal alternative for testing.
Smart Images

Figure 112023014363679-PAT00002_ABST
Abstract
Description
Technology Field
[0001] The present invention relates to a method for manufacturing a three-dimensional skin tissue model similar to atopic dermatitis and a method for screening atopic dermatitis therapeutic agents using the same. More specifically, the invention relates to a method for manufacturing a three-dimensional skin tissue model similar to atopic dermatitis through treatment with a cytokine mix and a method for screening atopic dermatitis therapeutic agents using the three-dimensional skin tissue model similar to atopic dermatitis manufactured therefrom. In addition, the cytokine mix and Staphylococcus aureus ( Straphylococcus aureus The present invention relates to a method for manufacturing a three-dimensional skin tissue model similar to atopic dermatitis through processing, and a screening method for atopic dermatitis treatments using the three-dimensional skin tissue model similar to atopic dermatitis manufactured therefrom. Background Technology
[0003] Atopic dermatitis is a chronic inflammatory skin disease characterized by severe itching and generalized dry skin, with eczematous lesions recurring in specific areas. It exhibits a genetic predisposition and is associated with an allergic march, which is accompanied by allergic diseases such as food allergies, allergic asthma, and allergic rhinitis (Akiharu Kubo et al., J Clin Invest. 122(2):440-447, 2012; Hywel CW et al., N Engl J Med, 352:2314-2324, 2005). Today, the etiology of atopic dermatitis is broadly divided into etiologies related to the skin barrier and etiologies related to abnormal immune responses. It is reported that mutations in the filaggrin gene occur in about 40% of patients with atopic dermatitis, and are more common in cases of severe symptoms or when the condition persists into adulthood. In addition, in people with a congenitally damaged skin barrier, external allergens penetrate the stratum corneum more easily, causing sensitization to the body and inducing atopic dermatitis.
[0004] Filaggrin, loricrin, and involucrin are known to be key proteins constituting the skin barrier involved in the pathogenesis of atopic dermatitis, playing an important role in the formation of the stratum corneum. Among these, filaggrin is considered a representative genetic factor of atopic dermatitis. Filaggrin mutations are the primary causes of atopic dermatitis, asthma, and allergic rhinitis; when mutations are present, there is a possibility that the condition may manifest as more severe clinical manifestations that persist into adult atopic dermatitis. Furthermore, it has been reported that in individuals without filaggrin mutations, acute atopic dermatitis lesions show reduced filaggrin expression compared to normal areas (Hyunjung Kim et al., Allergy Asthma Respir Dis 1(1):20-28, March 2013).
[0005] Furthermore, high concentrations of TSLP (Thymic stromal lymphopoietin) are present in the keratinocytes of patients with atopic dermatitis. TSLP is the apex protein of abnormal signal transduction. When allergens penetrate the body, substances such as TSLP stimulate dendritic cells to react, and it is during this process that the symptoms of atopic dermatitis appear. TSLP is CD11c + It stimulates dendritic cells to increase the production of TARC (Thymus and activation-regulated chemokine) and MDC. The concentration of these TSLPs is closely associated with the symptoms of atopic dermatitis (Holgate ST et al., Trends in Immunology, 28:248-251, 2007).
[0006] Furthermore, the main immunological changes in atopic dermatitis are an increase in IgE and an imbalance between T helper type 1 (Th1) cells and T helper type 2 (Th2) cells. Since Th1 cell activity decreases, the cytokines IL-2 and IFN-γ induced by Th1 cells decrease, while since Th2 cell activity increases, the cytokines IL-4, IL-5, IL-6, and IL-10 induced by them increase. Additionally, inflammation and damage to skin tissues lead to the overexpression of IL-3, IL-4, IL-5, IL-10, and Granulocyte-macrophage colony stimulating factor (GM-CSF), and the inflammatory cytokine IL-8 also increases (In-hwan Baek et al., Kor. J. Clin. Pharm., Vol. 17, No. 2. 2007).
[0008] Meanwhile, the 3D skin model is a Reconstructed Human Epidermis (RhE) model that reconstructs the human epidermis three-dimensionally by inducing the differentiation of keratinocytes, the major cells constituting the human epidermis, in an air-liquid interface cell culture. This enables numerous studies, including the evaluation of skin irritation, phototoxicity, and corrosiveness. EPISKIN TM , EpiDerm TM , SkinEthic TM , KeraSkin TM Artificial skin models such as the back have been listed in the OECD guidelines, having been certified for their usefulness as an irritation test method to replace animal testing through various validation studies.
[0010] Against this background, the inventors endeavored to develop an animal-alternative atopic dermatitis model capable of reflecting the human biological environment as much as possible using relatively easy-to-obtain normal skin tissue cells. As a result, they confirmed that findings of atopic dermatitis appeared in a three-dimensional skin tissue model treated with a cytokine complex containing IL-4, IL-13, IL-22, and TNF-α, and additionally Staphylococcus aureus ( Straphylococcus aureus It was confirmed that the characteristics of atopic dermatitis are more accurately realized in a 3D skin tissue model processed with ). Accordingly, by revealing that the above model can be used as a 3D skin tissue model similar to atopic dermatitis, the present application was made. The problem to be solved
[0012] The objective of the present invention is to provide a method for manufacturing a three-dimensional skin tissue model similar to atopic dermatitis and a screening method for atopic dermatitis treatments using the three-dimensional skin tissue model similar to atopic dermatitis manufactured therefrom. means of solving the problem
[0014] To achieve the objective of the present invention, the present invention provides a method for manufacturing an atopic dermatitis-like three-dimensional skin tissue model comprising the following steps:
[0015] (a) treating a three-dimensional skin tissue model with a cytokine complex composed of IL-4, IL-13, IL-22, and TNF-α; and
[0016] (b) A step of confirming the expression of one or more of skin barrier and epidermal cell differentiation factors, atopic dermatitis disease markers and proinflammatory cytokines in the above-processed three-dimensional skin tissue model.
[0017] In addition, the present invention relates to Staphylococcus aureus (in the three-dimensional skin tissue model of step (a) above) Straphylococcus aureusThe present invention provides a method for manufacturing a three-dimensional skin tissue model similar to atopic dermatitis, which further includes processing ).
[0018] In addition, the present invention provides an atopic dermatitis-like three-dimensional skin tissue model manufactured by the above method.
[0019] In addition, the present invention provides a screening method for an atopic dermatitis treatment using an atopic dermatitis-like three-dimensional skin tissue model comprising the following steps:
[0020] (a) a step of treating an atopic dermatitis-like 3D skin tissue model prepared by the above method with a candidate substance for an atopic dermatitis treatment; and
[0021] (b) A step of confirming the expression of one or more of skin barrier and epidermal cell differentiation factors, atopic dermatitis disease markers and pro-inflammatory cytokines in a skin tissue model treated with the above-mentioned atopic dermatitis treatment candidate substance. Effects of the invention
[0023] In the present invention, when a cytokine complex containing IL-4, IL-13, IL-22, and TNF-α was treated to a three-dimensional skin tissue model, a decrease in the expression of filaggrin, involucrin, loricrin, and cytokeratin-10, which are skin barrier and epidermal cell differentiation factors important findings in skin lesions of atopic dermatitis, was observed, and an increase in the expression of TSLP (Thymic stromal lymphopoietin), CA2 (carbonic anhydrase 2), and NELL2 (neural EGFL like 2), which are disease markers of atopic dermatitis, as well as the expression of proinflammatory cytokines CXCL10, IL-6, and IL-8 was observed, and histopathologically, spongiosis characteristics were mimicked, and physically, interepithelial electrical resistance (TEER) was confirmed to be reduced.
[0024] In addition, when the above 3D skin tissue model was treated with dexamethasone, a candidate substance for the treatment of atopic dermatitis, it was confirmed that the expression of the skin barrier and epidermal cell differentiation factors increased, and the expression of atopic dermatitis disease markers and pro-inflammatory cytokines decreased.
[0025] In addition, the above cytokine complex and additionally Staphylococcus aureus ( Straphylococcus aureus It was confirmed that findings of atopic dermatitis were more accurately realized in a 3D skin tissue model treated with ).
[0026] Accordingly, a three-dimensional skin tissue model prepared through cytokine complex treatment according to the method of the present invention and the cytokine complex and Staphylococcus aureus ( Straphylococcus aureus The 3D skin tissue model produced through the treatment can be usefully utilized as a new animal alternative testing method for evaluating the efficacy and studying the mechanism of action of atopic dermatitis treatments, as it is a 3D skin tissue model similar to atopic dermatitis. Brief explanation of the drawing
[0028] Figure 1a is a figure confirming the gene expression of skin barrier and epidermal cell differentiation factors, filaggrin (FLG), involucrin (IVL), loricrin (LOR), and cytokeratin-10 (KRT10), in an atopic dermatitis-like 3D skin tissue model prepared by treatment with a cytokine complex according to one embodiment of the present invention. FIG. 1b is a figure showing the gene expression of atopic dermatitis disease markers TSLP (Thymic stromal lymphopoietin), CA2 (carbonic anhydrase 2), and NELL2 (neural EGFL like 2) in an atopic dermatitis-like 3D skin tissue model prepared through treatment with a cytokine complex according to one embodiment of the present invention. FIG. 1c is a figure confirming the gene expression of pro-inflammatory cytokines CXCL10, IL-6, and IL-8 in an atopic dermatitis-like three-dimensional skin tissue model prepared through treatment with a cytokine complex according to one embodiment of the present invention. FIG. 2a is a figure showing the histopathological characteristics of an atopic dermatitis-like three-dimensional skin tissue model prepared through cytokine complex treatment according to one embodiment of the present invention. FIG. 2b is a figure showing the interepithelial electrical resistance (TEER) in an atopic dermatitis-like three-dimensional skin tissue model prepared through cytokine complex treatment according to one embodiment of the present invention. FIG. 3a is a figure showing the gene expression of atopic dermatitis disease markers CA2 and NELL2, and pro-inflammatory cytokines IL-6 and IL-8, after treating an atopic dermatitis-like 3D skin tissue model prepared through cytokine complex treatment according to one embodiment of the present invention with dexamethasone, a candidate substance for atopic dermatitis treatment. FIG. 3b is a figure showing the expression of the pro-inflammatory cytokines IL-6 and IL-8, and the pruritus-related protein TSLP, a disease marker for atopic dermatitis, after treating a 3D skin tissue model similar to atopic dermatitis prepared through treatment with a cytokine complex according to one embodiment of the present invention with dexamethasone, a candidate substance for atopic dermatitis treatment. FIG. 3c is a figure confirming the expression of skin barrier and epidermal cell differentiation factors filaggrin, involucrin, loricrin, and cytokeratin-10, and itch-related protein TSLP in a 3D skin tissue model similar to atopic dermatitis prepared through cytokine complex treatment according to one embodiment of the present invention, after treating the model with dexamethasone, a candidate substance for atopic dermatitis treatment. FIG. 3d is a figure showing the interepithelial electrical resistance (TEER) after treating an atopic dermatitis-like 3D skin tissue model prepared through cytokine complex treatment according to one embodiment of the present invention with dexamethasone, a candidate substance for treating atopic dermatitis. FIG. 4a shows a three-dimensional skin tissue model similar to atopic dermatitis prepared by treatment with a cytokine complex according to one embodiment of the present invention, and a cytokine complex and additionally Staphylococcus aureus ( Straphylococcus aureus This is a diagram confirming the gene expression of CA2, an atopic dermatitis disease marker, and IL-6 and IL-8, pro-inflammatory cytokines, in an atopic dermatitis-like 3D skin tissue model prepared through treatment. FIG. 4b shows a three-dimensional skin tissue model similar to atopic dermatitis prepared by treatment with a cytokine complex according to an embodiment of the present invention, and a cytokine complex and additionally Staphylococcus aureus ( Straphylococcus aureus This is a diagram confirming the histopathological characteristics of an atopic dermatitis-like 3D skin tissue model manufactured through ) treatment. Specific details for implementing the invention
[0029] The present invention will be described in more detail below.
[0031] The present invention provides a method for manufacturing an atopic dermatitis-like three-dimensional skin tissue model comprising the following steps:
[0032] (a) treating a three-dimensional skin tissue model with a cytokine complex composed of IL-4, IL-13, IL-22, and TNF-α; and
[0033] (b) A step of confirming the expression of one or more of skin barrier and epidermal cell differentiation factors, atopic dermatitis disease markers and proinflammatory cytokines in the above-processed three-dimensional skin tissue model.
[0034] In the method of the present invention, the cells constituting the three-dimensional skin tissue model may be human keratinocytes.
[0035] In the method of the present invention, the cytokine complex may be prepared by mixing IL-4, IL-13, IL-22, and TNF-α in a weight ratio of 1 to 10:1 to 10:1 to 10:1, specifically by mixing in a weight ratio of 1 to 8:1 to 8:1 to 8:1, and more specifically by mixing in a weight ratio of 1 to 6:1 to 6:1 to 6:1, but is not limited thereto.
[0036] In the method of the present invention, the cytokine complex may be treated at 5 to 200 ng / mL, specifically at 10 to 180 ng / mL, more specifically at 20 to 160 ng / mL, and more specifically at 25 to 150 ng / mL, but is not limited thereto.
[0037] In addition, the above cytokine complex may be treated for 12 to 108 hours, specifically for 18 to 102 hours, and more specifically for 24 to 96 hours, but is not limited thereto.
[0038] In the method of the present invention, the skin barrier and epidermal cell differentiation factors may be one or more of filaggrin, involucrin, loricrin, and cytokeratin-10, and a three-dimensional skin tissue model similar to atopic dermatitis may be obtained by confirming the expression of the skin barrier and epidermal cell differentiation factors. Specifically, a three-dimensional skin tissue model in which the expression of the skin barrier and epidermal cell differentiation factors is reduced compared to the control group may be obtained as a three-dimensional skin tissue model similar to atopic dermatitis.
[0039] In the method of the present invention, the atopic dermatitis disease marker may be one or more of TSLP (Thymic stromal lymphopoietin), CA2 (carbonic anhydrase 2), and NELL2 (neural EGFL like 2), and an atopic dermatitis-like 3D skin tissue model may be obtained by confirming the expression of the atopic dermatitis disease marker. Specifically, a 3D skin tissue model in which the expression of the atopic dermatitis disease marker increases compared to the control group may be obtained as an atopic dermatitis-like 3D skin tissue model.
[0040] In the method of the present invention, the pro-inflammatory cytokine may be one or more of CXCL10, IL-6, and IL-8, and a three-dimensional skin tissue model similar to atopic dermatitis may be obtained by confirming the expression of the pro-inflammatory cytokine. Specifically, a three-dimensional skin tissue model in which the expression of the pro-inflammatory cytokine increases compared to the control group may be obtained as a three-dimensional skin tissue model similar to atopic dermatitis.
[0041] Here, the control group refers to a three-dimensional skin tissue model treated with PBS (Phosphate-Buffered Saline) or DMSO (Dimethyl sulfoxide).
[0042] In the method of the present invention, the expression confirmation may be the expression of a protein or a gene, and such expression may be confirmed by one or more of quantitative RT-PCR (Reverse transcription polymerase chain reaction), real-time RT-PCR, immunofluorescence, immunoblot analysis, enzyme immunoassay (ELISA), and immunohistochemical staining, but is not limited thereto.
[0043] In the method of the present invention, Staphylococcus aureus (in the three-dimensional skin tissue model of step (a) Straphylococcus aureus It may further include treating ). Specifically, in step (a), a cytokine complex consisting of IL-4, IL-13, IL-22, and TNF-α and Staphylococcus aureus ( Straphylococcus aureus ) can be processed simultaneously, and thereby an atopic dermatitis-like 3D skin tissue model that more accurately embodies the characteristics of atopic dermatitis can be obtained. For example, the above cytokine complex and Staphylococcus aureus ( Straphylococcus aureus When ) are treated simultaneously, pro-inflammatory cytokines are further activated, and the expression of atopic dermatitis disease markers, such as CA2 which is involved in maintaining cell pH, water transport, and ion homeostasis, and histological spongiosis are further increased, allowing for a more accurate representation of the characteristics of atopic dermatitis.
[0044] In addition, the above Staphylococcus aureus is 0.1 to 50 × 10 5 It can be processed into CFU, specifically 0.5 to 30 × 10 5 It can be processed into CFU, more specifically 1 to 10 × 10 5 It can be processed into CFU, and more specifically 1 to 5 × 10⁻⁶ 5 It can be processed into CFU, but is not limited to this.
[0045] In the method of the present invention, spongiosis or interepithelial electrical resistance (TEER) can be further confirmed in the three-dimensional skin tissue model of step (b). Specifically, a three-dimensional skin tissue model exhibiting spongiosis can be obtained as an atopic dermatitis-like three-dimensional skin tissue model, and a three-dimensional skin tissue model in which interepithelial electrical resistance (TEER) is reduced compared to the control group can be obtained as an atopic dermatitis-like three-dimensional skin tissue model. Here, the control group refers to a three-dimensional skin tissue model treated with PBS or DMSO.
[0047] In addition, the present invention provides an atopic dermatitis-like three-dimensional skin tissue model manufactured by the method according to the present invention.
[0048] In the present invention, the atopic dermatitis-like three-dimensional skin tissue model has reduced expression of one or more skin barrier and epidermal cell differentiation factors, specifically filaggrin, involucrin, loricrin, and cytokeratin-10, compared to the control group.
[0049] In the present invention, the atopic dermatitis-like three-dimensional skin tissue model has increased expression of one or more atopic dermatitis disease markers, specifically TSLP, CA2, and NELL2, compared to the control group.
[0050] In the present invention, the atopic dermatitis-like three-dimensional skin tissue model has increased expression of pro-inflammatory cytokines, specifically one or more of CXCL10, IL-6, and IL-8, compared to the control group.
[0051] In the present invention, the atopic dermatitis-like three-dimensional skin tissue model exhibits spongiform dermatitis and has reduced interepithelial electrical resistance (TEER) compared to the control group.
[0052] Here, the control group refers to a three-dimensional skin tissue model treated with PBS or DMSO.
[0054] In addition, the present invention provides a screening method for an atopic dermatitis treatment using an atopic dermatitis-like three-dimensional skin tissue model comprising the following steps:
[0055] (a) a step of treating an atopic dermatitis-like three-dimensional skin tissue model prepared by the method according to the present invention with a candidate substance for an atopic dermatitis treatment; and
[0056] (b) A step of confirming the expression of one or more of skin barrier and epidermal cell differentiation factors, atopic dermatitis disease markers and pro-inflammatory cytokines in a skin tissue model treated with the above-mentioned atopic dermatitis treatment candidate substance.
[0057] In the method of the present invention, the skin barrier and epidermal cell differentiation factors may be one or more of filaggrin, involucrin, loricrin, and cytokeratin-10, and a candidate substance may be selected as a treatment for atopic dermatitis by confirming the expression of the skin barrier and epidermal cell differentiation factors. Specifically, a candidate substance that increases the expression of the skin barrier and epidermal cell differentiation factors compared to a control group may be selected as a treatment for atopic dermatitis.
[0058] In the method of the present invention, the atopic dermatitis disease marker may be one or more of TSLP, CA2, and NELL2, and a candidate substance may be selected as an atopic dermatitis treatment by confirming the expression of the atopic dermatitis disease marker. Specifically, a candidate substance that reduces the expression of the atopic dermatitis disease marker compared to a control group may be selected as an atopic dermatitis treatment.
[0059] In the method of the present invention, the pro-inflammatory cytokine may be one or more of CXCL10, IL-6, and IL-8, and a candidate substance may be selected as a treatment for atopic dermatitis by confirming the expression of the pro-inflammatory cytokine. Specifically, a candidate substance that reduces the expression of the pro-inflammatory cytokine compared to a control group may be selected as a treatment for atopic dermatitis.
[0060] Here, the control group refers to an atopic dermatitis-like 3D skin tissue model without treatment with an atopic dermatitis treatment candidate, or an atopic dermatitis-like 3D skin tissue model treated with PBS or DMSO.
[0061] In the method of the present invention, the expression confirmation may be the expression of a protein or a gene, and such expression may be confirmed by one or more of quantitative RT-PCR, real-time RT-PCR, immunofluorescence, immunoblot analysis, enzyme immunoassay (ELISA), and immunohistochemical staining, but is not limited thereto.
[0062] In the method of the present invention, the candidate substance for treating atopic dermatitis can be selected as a treatment for atopic dermatitis by further confirming spongiformity or interepithelial electrical resistance (TEER) in a skin tissue model treated with the candidate substance for treating atopic dermatitis of step (b). Specifically, a candidate substance that reduces spongiformity and increases interepithelial electrical resistance (TEER) compared to a control group can be selected as a treatment for atopic dermatitis.
[0064] The present invention will be explained in detail below through examples.
[0065] However, the following examples are merely illustrative of the present invention, and the content of the present invention is not limited to the following examples.
[0067] <Example 1> Preparation of a 3D skin tissue model mimicking atopic dermatitis
[0068] <1-1> 3D Skin Model
[0069] 3D Skin Model (KeraSkinTM The 3D skin model (Biosolution) consists of 8 to 15 cell layers composed of normal human epithelial keratinocytes (NHEK) derived from penile foreskin tissue or adult breast tissue, which is similar to in vivo epithelial tissue having basal, spinous, granular, and cornified layers. In addition, the 3D skin model has metabolic and cell division activities and expresses mature epithelial-specific differentiation markers such as pro-filaggrin, K1 / K10 cytokeratin pair, involucrin, and type I epidermal transglutaminase. The above three-dimensional skin model can be cultured in DMEM (Dulbecco's Modified Eagle's Medium) containing epidermal growth factor, insulin, hydrocortisone, antibiotics, etc., while maintaining normal epidermal morphology for up to 5 weeks.
[0071] <1-2> Cytokine mix treatment
[0072] A 3D skin model of Example <1-1> was cultured using the Biosolution culture method, and then a cytokine complex of IL-4, IL-13, IL-22, and TNF-α mixed in a ratio of 5:5:5:1 was added to the culture medium at 75 ng / mL for 78 hours to produce a 3D skin tissue model similar to atopic dermatitis.
[0074] <1-3> Cytokine mix and Staphylococcus aureus ( Straphylococcus aureus ) processing
[0075] After culturing the 3D skin model of Example <1-1> above using the culture method of Biosolution, 75 ng / mL of a cytokine complex prepared by mixing IL-4, IL-13, IL-22, and TNF-α in a ratio of 5:5:5:1 and 2.5 × 10 5 Staphylococcus aureus in CFU / well ( Straphylococcus aureus A 3D skin tissue model resembling atopic dermatitis was prepared by treating the culture medium with ) for 78 hours.
[0077] <Experimental Example 1> Confirmation of expression of atopic dermatitis-related factors in an atopic dermatitis-like 3D skin tissue model prepared through treatment with a cytokine complex
[0078] In the atopic dermatitis-like 3D skin tissue model prepared in the above Examples <1-2>, the gene expression of skin barrier and epidermal cell differentiation factors Filaggrin (FLG), Involucrin (IVL), Loricrin (LOR), and Keratin-10 (also known as keratin-10, KRT10, or Cytokeratin-10 (CK10)), atopic dermatitis disease markers TSLP (Thymic stromal lymphopoietin), CA2 (carbonic anhydrase 2), and NELL2 (neural EGFL like 2), and proinflammatory cytokines CXCL10 (CXC motif chemokine ligand 10), IL-6 (interleukin 6), and IL-8 (interleukin 8) was measured by real-time quantitative PCR. confirmed.
[0079] Specifically, a 3D skin model was treated with a cytokine complex in the same manner as in Example <1-2> above, and then the 3D skin model was harvested. Next, the TRIzol reagent was added, and RNA was extracted according to the manufacturer's method. cDNA was synthesized from the extracted RNA using a cDNA synthesis kit (TaKaRa, Japan) according to the manufacturer's method. Real-time polymerase chain reaction was performed using the prepared cDNA as a template and the primers listed in [Table 1] below. In addition, a 3D skin model treated with PBS (Phosphate-Buffered Saline) instead of the cytokine complex was used as a control (Figs. 1a to 1c).
[0080] primer Sequence (5'→3') Sequence number FLG Forward direction AGACACTCTCAGCACGGAAG 1 reverse direction GGCCACATAAACCTGGGTCC 2 IVL Forward direction GCTCCTCAAGACTGTTCCTCC 3 reverse direction CAGGCAGTCCCTTTACAGCA 4 LOR Forward direction TCTCATGATGCTACCCGAGGTTTG 5 reverse direction GGGTTGGGAGGTAGTTGTACAGAA 6 KRT10 Forward direction CAACTCACATCAGGGGGAGC 7 reverse direction AGCCTGGCATTGTCGATCTG 8 TSLP Forward direction TGCCTTAGCTATCTGGTGCC 9 reverse direction TTGAAGCGACGCCACAATCC 10 CA2 Forward direction AACAATGGTCATGCTTTCAACG 11 reverse direction TGTCCATCAAGTGAACCCCAG 12 NELL2 Forward direction ATTACCGCTCAGGCAGTCAC 13 reverse direction GCCTAGAGGCAAGTCTGTGG 14 CXCL10 Forward direction CCTGCAAGCCAATTTTGTCCA 15 reverse direction AGACCTTTCCTTGCTAACTGCT 16 IL-6 Forward direction CCCCTGACCCAACCACAAAT 17 reverse direction CATTTGCCGAAGAGCCCTCA 18 IL-8 Forward direction TTCTGCAGCTCTGTGTGAAGG 19 reverse direction TAATTTCTGTGTTGGCGCAGTG 20 GAPDH Forward direction CAAATTCCATGGCACCGTCA 21 reverse direction GACTCCACGACGTACTCAGC 22
[0081] As a result, as shown in Fig. 1a, the control group (KeraSkin TM Compared to the atopic dermatitis-like 3D skin tissue model (KeraSkin-AD) prepared in Example <1-2> above TM In ), the expression of the genes IVL, FLG, LOR, and KRT10, which are skin barrier and epidermal cell differentiation factors, was significantly reduced.
[0082] In addition, as shown in Fig. 1b, the control group (KeraSkin TM Compared to the atopic dermatitis-like 3D skin tissue model (KeraSkin-AD) prepared in Example <1-2> above TM Gene expression of CA2, NELL2, and TSLP, which are disease markers of atopic dermatitis, was significantly increased in ).
[0083] In addition, as shown in Fig. 1c, the control group (KeraSkin TM Compared to the atopic dermatitis-like 3D skin tissue model (KeraSkin-AD) prepared in Example <1-2> above TM The gene expression of the pro-inflammatory cytokines CXCL10, IL-8, and IL-6 was significantly increased in ).
[0084] Through the above results, it can be seen that the three-dimensional skin tissue model prepared by cytokine complex treatment according to the method of the present invention exhibits findings similar to atopic dermatitis.
[0086] <Experimental Example 2> Confirmation of Histopathological and Physical Changes in an Atopic Dermatitis-Similar 3D Skin Tissue Model Prepared via Cytokine Complex Treatment
[0087] Histopathological changes in the atopic dermatitis-like 3D skin tissue model prepared in the above Example <1-2> were confirmed by H&E staining, and physical changes were confirmed by measuring interepithelial electrical resistance (TEER).
[0088] Specifically, a cytokine complex was treated on a 3D skin model in the same manner as in Example <1-2> above, and then the 3D skin model was harvested, fixed in 4% formaldehyde (Sigma, USA), and embedded in paraffin to prepare slides. The tissue slides were stained with hematoxylin and eosin (H&E), and histopathological changes were observed using an optical microscope (Olympus, Tokyo, Japan) (Fig. 2a).
[0089] In addition, a 3D skin model was treated with a cytokine complex in the same manner as in Example <1-2>, the 3D skin model was collected and placed in a bath, and the epithelial potential difference and short-circuit current were determined using an Ag-AgCl electrode with a voltage clamp corrected for fluid resistance, and the interepithelial electrical resistance (TEER) was calculated according to Ohm's law. Additionally, a 3D skin model treated with PBS instead of the cytokine complex was used as a control (Fig. 2b).
[0090] As a result, as shown in Fig. 2a, spongiosis, the most significant histopathological feature of atopic dermatitis, was realized in the atopic dermatitis-like 3D skin tissue model prepared in Example <1-2>, and skin barrier damage was observed.
[0091] In addition, as shown in Fig. 2b, the control group (KeraSkin TM Compared to the atopic dermatitis-like 3D skin tissue model (KeraSkin-AD) prepared in Example <1-2> above TM It showed physical characteristics where TEER decreased in ).
[0092] Through the above results, it can be seen that the three-dimensional skin tissue model prepared by cytokine complex treatment according to the method of the present invention exhibits findings similar to atopic dermatitis.
[0094] <Experimental Example 3> Screening of Atopic Dermatitis Treatment Agents Using an Atopic Dermatitis-Similar 3D Skin Tissue Model Prepared by Cytokine Complex Treatment
[0095] After treating the atopic dermatitis-like 3D skin tissue model prepared in Example <1-2> with dexamethasone as a candidate substance for atopic dermatitis treatment, the gene expression of CA2 and NELL2, which are disease markers of atopic dermatitis, and the pro-inflammatory cytokines IL-6 and IL-8 was confirmed by real-time polymerase chain reaction. In addition, the expression of the pro-inflammatory cytokines IL-6 and IL-8 and the expression of TSLP protein, a pruritus-related factor and atopic dermatitis disease marker, were confirmed by enzyme immunoassay (ELISA), the expression of skin barrier and epidermal cell differentiation factors and TSLP protein within the tissue was confirmed by immunohistochemical staining, and physical changes were confirmed by measuring TEER.
[0096] Specifically, a cytokine complex was treated to a 3D skin model using the method described in Example <1-2> above, followed by treatment with dexamethasone (DEX) either untreated or at 100 μM for 24 hours. After 24 hours, the 3D skin model was collected, and real-time polymerase chain reaction was performed using the same method described in Experimental Example 1 above to confirm the gene expression of CA2, NELL2, IL-6, and IL-8 (Fig. 3a).
[0097] In addition, in the same manner as above, dexamethasone (DEX) was either untreated or treated with 20 μM for 48 hours, and a 3D skin model was collected, after which ELISA was performed according to the manufacturer's method using an IL-6, IL-8, and TSLP ELISA kit (R&D Systems, USA) (Fig. 3b).
[0098] In addition, a 3D skin model was collected using the same method as above, either untreated or treated with 20 μM dexamethasone (DEX), and H&E staining was performed using the method described in <Experimental Example 2>. Furthermore, the collected 3D skin model was fixed in 4% formaldehyde (Sigma, USA) and then embedded in paraffin to prepare a slide. The tissue slide was subjected to a deparinization process using xylene and a dehydration process using alcohol. Afterward, the slide was immersed in citrate buffer, microwaved for 10 minutes, and then cooled at room temperature for one hour. The slide was washed with distilled water, reacted with 5% goat serum at room temperature for one hour, and then incubated with antibodies for each factor diluted 1:50. After reacting with an HRP-conjugated secondary antibody, color development was performed using a DAB kit to confirm changes in the expression of filaggrin, involucrin, loricrin, cytokeratin-10, and TSLP proteins in the tissue (Fig. 3c).
[0099] In addition, 0, 20, 100, and 200 μM of dexamethasone (DEX) were treated in the same manner as above, and a 3D skin model was collected, after which TEER was measured using the method described in <Experimental Example 2> above (Fig. 3d).
[0100] In the above experiment, a 3D skin model treated with PBS was used as a control instead of the cytokine complex.
[0101] As a result, as shown in FIG. 3a, the atopic dermatitis-like 3D skin tissue model (KeraSkin-AD) prepared in Example <1-2> above TM Compared to ) when treated with dexamethasone (KeraSkin-AD TM + Dexamethasone) The gene expression of CA2, NELL2, IL-6, and IL-8 was reduced.
[0102] In addition, as shown in Fig. 3b, the control group (KeraSkin TM Compared to the atopic dermatitis-like 3D skin tissue model (KeraSkin-AD) prepared in Example <1-2> above TM While CXCL10, IL-8, and TSLP protein expression increased in ), when dexamethasone was treated (KeraSkin-AD TM + 20 μM DEX) These expressions decreased.
[0103] In addition, as shown in Fig. 3c, the control group (KeraSkin TM Compared to the atopic dermatitis-like 3D skin tissue model (KeraSkin-AD) prepared in Example <1-2> above TM The expression of filaggrin, involucrin, loricrin, and CK10 in the tissue decreased, and TSLP protein expression increased, whereas in the case of dexamethasone treatment (KeraSkin-AD TM The expression of these (+ Dexamethasone) was restored to a level similar to the control group.
[0104] In addition, as shown in FIG. 3d, the atopic dermatitis-like 3D skin tissue model (KeraSkin-AD) prepared in Example <1-2> above TM The reduced TEER in ) increased in a concentration-dependent manner when treated with dexamethasone (DEX 20 μM, 100 μM, 200 μM).
[0105] Through the above results, it can be seen that the three-dimensional skin tissue model prepared by cytokine complex treatment according to the method of the present invention can be used as an atopic dermatitis-like three-dimensional skin tissue model for screening atopic dermatitis treatments.
[0107] <Experimental Example 4> Confirmation of expression of atopic dermatitis-related factors in an atopic dermatitis-like 3D skin tissue model prepared by treatment with a cytokine complex and Staphylococcus aureus
[0108] Gene expression of CA2, IL-6, and IL-8 in the atopic dermatitis-like 3D skin tissue model prepared in the above Examples <1-3> was confirmed by real-time polymerase chain reaction, and histopathological changes were confirmed by H&E staining.
[0109] Specifically, a 3D skin model was treated with a cytokine complex and Staphylococcus aureus in the same manner as in Example <1-3>, and then the 3D skin model was collected. Subsequently, a real-time polymerase chain reaction (Fig. 4a) and H&E staining (Fig. 4b) were performed in the same manner as described in Experimental Example 1 and Experimental Example 2. In addition, gene expression was compared with the 3D skin model of Example <1-1> and the atopic dermatitis-like 3D skin tissue model prepared through the treatment with the cytokine complex of Example <1-2>.
[0110] As a result, as shown in Fig. 4a, the control group (KeraSkin TM Compared to the atopic dermatitis-like 3D skin tissue model (KeraSkin-AD) prepared in Examples <1-3> above TM (with S. aureus)) gene expression of CA2, IL-6, and IL-8 was significantly increased. In addition, the atopic dermatitis-like 3D skin tissue model (KeraSkin-AD) prepared in the above Examples <1-2> TM It was found that the expression of these genes increased significantly even compared to (No S. aureus).
[0111] In addition, as shown in FIG. 4b, the atopic dermatitis-like 3D skin tissue model (KeraSkin-AD) prepared in Example <1-2> above TM Compared to the atopic dermatitis-like 3D skin tissue model (KeraSkin-AD) prepared in Examples <1-3> above (with S. aureus), the atopic dermatitis-like 3D skin tissue model prepared in Examples <1-3> above is different. TM Increased histological spongiosis was confirmed in (with S. aureus).
[0112] Through the above results, it can be seen that the three-dimensional skin tissue model prepared by treatment with a cytokine complex and Staphylococcus aureus according to the method of the present invention is a three-dimensional skin tissue model similar to atopic dermatitis, and that the characteristics of atopic dermatitis are more accurately realized.
Claims
Claim 1 A method for preparing an atopic dermatitis-like three-dimensional skin tissue model comprising the following steps: (a) a cytokine complex composed of IL-4, IL-13, IL-22, and TNF-α and Staphylococcus aureus ( Straphylococcus aureus (a) a step of processing ) and (b) confirming the expression of one or more of skin barrier and epidermal cell differentiation factors, atopic dermatitis disease markers, and proinflammatory cytokines and spongiosis in the processed 3D skin tissue model, and obtaining a 3D skin tissue model in which, compared to an untreated control group, (i) the expression of the skin barrier and epidermal cell differentiation factors is decreased, (ii) the expression of the atopic dermatitis disease markers is increased, (iii) the expression of proinflammatory cytokines is increased, and (iv) spongiosis is induced. Claim 2 A method for manufacturing an atopic dermatitis-like three-dimensional skin tissue model, wherein, in claim 1, the cells constituting the three-dimensional skin tissue model are human keratinocytes. Claim 3 A method for preparing an atopic dermatitis-like three-dimensional skin tissue model according to claim 1, wherein the cytokine complex is treated at 5 to 120 ng / mL for 12 to 108 hours. Claim 4 A method for preparing a three-dimensional skin tissue model similar to atopic dermatitis according to claim 1, wherein the skin barrier and epidermal cell differentiation factors are one or more of filaggrin, involucrin, loricrin, and cytokeratin-10. Claim 5 delete Claim 6 A method for manufacturing an atopic dermatitis-like three-dimensional skin tissue model, wherein, in claim 1, the atopic dermatitis disease marker is one or more of TSLP, CA2, and NELL2. Claim 7 delete Claim 8 A method for preparing a three-dimensional skin tissue model similar to atopic dermatitis according to claim 1, wherein the pro-inflammatory cytokine is one or more of CXCL10, IL-6, and IL-8. Claim 9 delete Claim 10 delete Claim 11 A method for preparing a three-dimensional skin tissue model similar to atopic dermatitis according to claim 1, wherein the confirmation of expression in step (b) is confirmed by one or more of quantitative RT-PCR (Reverse transcription polymerase chain reaction), real-time RT-PCR, immunofluorescence, immunoblot analysis, enzyme immunoassay (ELISA), and immunohistochemical staining. Claim 12 A method for manufacturing an atopic dermatitis-like 3D skin tissue model, wherein, in claim 1, the interepithelial electrical resistance (TEER) in the 3D skin tissue model of step (b) is additionally confirmed. Claim 13 delete Claim 14 A method for manufacturing an atopic dermatitis-like 3D skin tissue model, wherein, in claim 12, a 3D skin tissue model having reduced interepithelial electrical resistance (TEER) compared to a control group is obtained as an atopic dermatitis-like 3D skin tissue model. Claim 15 delete Claim 16 A screening method for an atopic dermatitis therapeutic agent using an atopic dermatitis-like three-dimensional skin tissue model comprising the following steps: (a) treating an atopic dermatitis-like three-dimensional skin tissue model prepared by the method of any one of claims 1 to 4, 6, 8, 11, 12, and 14 with an atopic dermatitis therapeutic agent candidate; and (b) confirming the expression of one or more of a skin barrier and epidermal cell differentiation factors, an atopic dermatitis disease marker, and a pro-inflammatory cytokine, and spongiosis in the skin tissue model treated with the atopic dermatitis therapeutic agent candidate.
Citation Information
Patent Citations
Use of the human-X vivo skin model and its method for identifying modulators of skin inflammation
JP2015529817A
Animal model of atopic dermatitis and its use
JP6362011B2
Juvenile Atopic Dermatitis Models
US20190234939A1
